Reports Q1 revenue $36.6M, consensus $2.8M. “The first quarter was about focus at HOOKIPA. We are embarking on a pivotal trial for HB-200 in combination with pembrolizumab and made important decisions to align our organization for late-stage clinical trial execution. We also added to the depth of our executive team with a new Chief Development Officer, Mark Winderlich, who brings crucial experience to help us execute on our clinical development strategy,” said Joern Aldag, Chief Executive Officer of HOOKIPA. “We have made great progress and have an FDA-aligned pivotal Phase 2/3 trial design that is patient-centric and we believe has a high probability of success. Our path forward is clear, and the team is excited to take a major step on our path to deliver better outcomes for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Hookipa Pharma price target lowered to $5 from $6.50 at H.C. Wainwright
- Hookipa Pharma Announces Major HB-200 Clinical Trial Design
- Hookipa Pharma announces Phase 2/3 trial design for HB-200
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab